Effects of Cholecalciferol on Functional, Biochemical, Vascular, and Quality of Life Outcomes in Hemodialysis Patients.
Clin J Am Soc Nephrol. 2013 Mar 14.
Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ.
Postgraduate Medical School, University of Notre Dame, Sydney, Australia;, †Renal Resource Centre, Sydney Dialysis Centre, Royal North Shore Hospital, Sydney, Australia;, ‡Department of Renal Medicine, Westmead Hospital, Sydney, Australia, §Osteoporosis and Bone Biology Division, Garvan Institute of Medical Research, Sydney, Australia.
BACKGROUND AND OBJECTIVES: Observational studies suggest that calciferol supplementation may improve laboratory and patient-level outcomes of hemodialysis patients with reduced 25-hydroxyvitamin D [25(OH)D] levels. This randomized controlled trial examined effects of cholecalciferol supplementation in patients on hemodialysis.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sixty patients with 25(OH)D levels ≤24 ng/ml (≤60 nmol/L) were randomized to receive 50,000 IU oral cholecalciferol or placebo, once weekly for 8 weeks and then monthly for 4 months. At baseline (autumn 2011) and 6 months, testing evaluated muscle strength, functional capacity, laboratory parameters, pulse wave velocity (PWV), and health-related quality of life (HRQOL) using the Kidney Disease Quality of Life-36 survey.
RESULTS: Patients were well matched by treatment allocation. Median age was 62 years (range, 20-86), 52% were women, 55% had a history of diabetes, and mean serum 25(OH)D was 17±5 ng/ml (43±13 nmol/L). Patients were assessed over 6 months by repeated-measures ANOVA. Patients allocated to cholecalciferol had significantly higher values of 25(OH)D (P<0.001), 1,25-dihydroxyvitamin D (P=0.04), and tartrate-resistant acid phosphatase-5b) (P=0.04) and a greater reduction in phosphorus values (P=0.03) than placebo-treated patients Values of serum calcium, intact parathyroid hormone, and episodes of hypercalcemia and hyperphosphatemia did not differ significantly between the groups. No significant differences were detected in muscle strength, functional capacity, PWV, or HRQOL.
CONCLUSIONS: In this randomized controlled trial, patients supplemented with cholecalciferol had higher 25(OH)D, 1,25-dihydroxyvitamin D, and tartrate-resistant acid phosphatase-5b levels, without increased calcium or phosphorus values. However, no effects were detected in muscle strength, functional capacity, PWV, or HRQOL.
- Overview Kidney and vitamin D
- Vitamin D3 becomes Calcidiol which becomes Calcitriol
- 2000 IU vitamin D3 was not enough for children with chronic kidney disease – Feb 2013
- Kidney Conference had many Vitamin D papers – May 2012
- 7100 IU (50000 weekly) restored vitamin D levels for those with Chronic Kidney Disease – July 2012
- 25,0000 IU vitamin D weekly only raised 60 percent on hemodialysis above 30 ng – Nov 2014
- Need at least 80 ng of vitamin D if have chronic kidney disease – May 2012
- Kidney failure and vitamin D deficiency vicious cycle – Jan 2011
- Kidney disease requires magnesium - Jan 2013
- 50 percent of Chronic Kidney Disease treatments in Germany include vitamin D – Dec 2012
- Kidney Dialysis clinics reluctant to add vitamin D treatment as they are not reimbursed – Oct 2012